Every intervention Outliyr has scored for traumatic brain injury, ranked by its BioHarmony score for this use case rather than its overall rating. The number beside each name is how well that one thing works for traumatic brain injury; the tier beside it is what it is worth once safety, cost and effort are counted across everything else.
30 of 89 evaluated interventions score 3.0+ out of 10 for traumatic brain injury · 5 comparisons
TBI is a strong practical use case among clinicians and athletes, but the literature is still not definitive. May 2013 found all reviewed studies reported positive findings while also flagging missing placebo-controlled…
Vasireddi 2025 anchors the most relevant signal. BPC-157 fits tbi when the target is tissue repair, vascular recruitment, or inflammation control, but the case still rests mostly on preclinical models. The score…
Tan, Dao, Farmer, Sutherland, Gevirtz 2011 supports a plausible benefit. Systematic review of 7 studies; RCT data show improved executive function post-TBI in supervised clinical protocols. The score stays bounded because HRV…
TBI scoring is based on animal evidence, especially Xiong 2012 showing neuroprotective and neurorestorative effects after experimental traumatic brain injury. This is promising preclinical biology, not a human TBI treatment recommendation. That…
Post-concussion autonomic dysregulation is a good mechanistic fit; clinical evidence remains pilot-stage, so tVNS is best treated as an adjunct to rehab and clinician-guided care. The score stays bounded because Vagus Nerve…
TBI evidence is mixed but meaningful for chronic persistent post-concussion protocols. Boussi-Gross 2013 reports cognitive and quality-of-life improvements after forty sessions. Hadanny 2018 supports a retrospective cohort. Wolf 2012 prevents a high…
Lang 2024 is the cleanest verified anchor for this report. The existing rationale points to this narrower claim: Subsymptom aerobic exercise is used in some post-concussion rehabilitation models, but TBI progression should…
Soh 2024 anchors the most relevant signal. Glycine fits tbi because glycine participates in sleep signaling, glutathione, collagen, methylation, and nervous-system balance, depending on the endpoint. The score stays bounded because many…
Traumatic brain injury data are rodent-only but consistent and reproducible. Tβ4 treatment improved sensorimotor and cognitive function and increased neurogenesis in rat controlled cortical impact even when treatment started 6 hours post-injury,…
Semaglutide has no TBI-specific clinical evidence in this report, even though GLP-1 neuroprotection is mechanistically interesting. Yao 2024 supports metabolic benefits, which may matter indirectly for brain recovery if diabetes or obesity…
No direct traumatic brain injury evidence was verified. Protein adequacy may support recovery nutrition, but EAA-specific claims are not established.
TBI support is mechanistically interesting and community-reported, but there is no human TBI RCT. Treat Lion's Mane as experimental adjunctive support only.
TBI relevance comes from overlapping neuroprotection, BDNF, and ischemia-stress mechanisms, not from a dedicated traumatic-brain-injury RCT.
No direct TBI evidence. Vestibular and balance considerations may matter clinically, but TBI-specific benefit claims would be premature.
No direct traumatic-brain-injury evidence. Do not borrow from unrelated mitochondrial or neuroplasticity interventions.
Traumatic brain injury is one of Cerebrolysin's better-supported uses, with a small-to-medium recovery effect in moderate-to-severe injury, which is why it scores moderate-to-high rather than higher. The single-center CAPTAIN II trial in…
INSUFFICIENT_EVIDENCE for traumatic brain injury recovery in humans, despite broad neuroinflammation and autophagy hypotheses.
TBI remains low and exploratory. Zhang 2018 supports neuronal apoptosis protection after brain hemorrhage in rats, but traumatic-brain-injury outcomes in humans are untested.
No direct TBI evidence supports metformin as a brain-injury protocol. Any neuroprotection discussion remains diabetes-confounded or preclinical.
DHA has a credible brain-repair rationale, but TBI clinical evidence is not yet practice-changing.
An independent non-Salk lab showed J-147 improved motor and cognitive recovery and reduced contusion volume after traumatic brain injury (Jin et al. 2024). Promising independent replication, but a single study and animal-only.
Hypogonadism is common after traumatic brain injury, and replacement may help if true deficiency exists. TRT should be based on endocrine testing after TBI, not used as a generic brain-recovery protocol.
A small military mild-TBI signal exists alongside the neuroprotective mechanism, but the human outcome base is thin and not replicated at scale.
Post-acute exercise can support cognition and mood after brain injury, but high-intensity intervals do not belong in acute TBI management and require clinical progression.
Neuroprotective antioxidant data is mostly animal or mechanistic. No human TBI RCT base.
Preclinical traumatic brain injury models show mitochondrial stabilization and neuroprotection potential, but no human TBI trial was verified for SS-31.
Post-TBI pituitary dysfunction can involve GH deficiency, but tesamorelin itself has not been tested as a TBI therapy. Endocrine evaluation matters more than unsupervised peptide use.
Alternative brain fuel is a plausible mechanism after injury, but human exogenous-ketone TBI data is preclinical or absent.
Neurotrophic and synaptogenic mechanisms could matter after brain injury, but no direct TBI study exists for dihexa. This remains speculative despite the memory-model literature.
Nothing matches those filters.
Monthly out-of-pocket cost at the most accessible legitimate channel, at the dose the score was given for. 8 of 30 are not priced yet; those cells are left blank rather than guessed.
| Intervention | Monthly cost | At dose | How you get it |
|---|---|---|---|
| Neurofeedback | Not priced yet | ||
| BPC-157 | $40–$80 | 250 to 500 mcg SC 1 to 2x/day near injury site | Grey market |
| HRV Biofeedback | $5 | 20 min/session at individual RF (4.5 to 6.5 bpm) | Over the counter |
| TB-500 (Thymosin Beta-4 Fragment) | Not priced yet | ||
| Vagus Nerve Stimulation | $4–$8 | 10-20 min auricular tVNS at comfortable perceptible intensity | Over the counter |
| Hyperbaric Oxygen Therapy | $3,000–$6,000 | 2.0 ATA for 90 minutes with air breaks | In clinic |
| Zone 2 Cardio | Not priced yet | Over the counter | |
| Glycine | $2–$3 | 3 g oral glycine | Over the counter |
| Thymosin Beta-4 (Tβ4) | Not priced yet | ||
| Semaglutide | $199–$349 | 0.25 mg weeks 1 to 4, 0.5 mg weeks 5 to 8, 1.0 mg weeks 9 to 12, 1.7 mg weeks 13 to 16, 2.4 mg week 17 onward | Prescription |
| Essential Amino Acids | Not priced yet | ||
| Lion’s Mane | $20–$40 | 3 g/day fruiting body extract | Over the counter |
| Semax | $12–$60 | 300-600 mcg/day of 0.1% spray | Grey market |
| Whole-Body Vibration | $50–$100 | 30 Hz, roughly 0.3g, 10-20 min standing | Over the counter |
| Ca-AKG (Calcium Alpha-Ketoglutarate) | $15–$30 | 1 g/day generic Ca-AKG oral | Over the counter |
| Cerebrolysin | $500–$900 | About 30 mL per day IV | Grey market |
| Rapamycin | $15–$50 | 3 mg | Prescription |
| GHK-Cu | $30–$100 | 0.5-3% topical serum or cream | Over the counter |
| Metformin | $4–$30 | 500 mg with dinner for 1 week, then 500 mg twice daily for 1 week, then increase by 500 mg/week toward 1000 mg twice daily as tolerated | Prescription |
| Omega-3 | $20–$40 | 1-2 g/day combined EPA+DHA | Over the counter |
| J-147 | Not priced yet | ||
| TRT (Testosterone Replacement Therapy) | $50–$300 | Clinician-selected formulation at the lowest dose likely to restore physiologic testosterone | Prescription |
| NAC (N-Acetylcysteine) | $5–$15 | 600 to 1,200 mg/day | Over the counter |
| Norwegian 4×4 | Not priced yet | Over the counter | |
| Spermidine | $40–$90 | 1-3 mg/day oral WGE | Over the counter |
| Astaxanthin | Not priced yet | ||
| SS-31 (Elamipretide) | $200–$500 | 5-10 mg/day subcutaneous | Grey market |
| Tesamorelin | $250–$500 | 2 mg subcutaneous daily in the evening | Prescription |
| Exogenous Ketones | $38–$300 | Ester 10 to 25 g BHB | Over the counter |
| Dihexa | $30–$60 | 8-12 mg/day sublingual | Research use only |
Head-to-head reports and category rankings that name a winner on this use case.
Ranked by the live Focus and cognition subrating, not the overall score. Methylene blue leads at 6.5–7.0/10 despite a lower overall, 6.0–6.5/10. Bromantane climbs from ninth to fourth.…
Bromantane, for anything you plan to repeat. It scores 7.0–7.5/10 against phenylpiracetam's 5.5–6.0/10 and wins every shared use case that is not a floor tie: energy 6.2/10 to…
Cerebrolysin scores 6.0–6.5/10 and P-21 scores 5.0–5.5/10, and the gap is entirely about human data. Cerebrolysin has thousands of trial participants, contested by two independent Cochrane reviews. P-21…
Semax scores 7.0–7.5/10 and cerebrolysin 6.0–6.5/10. Semax wins cognition, neuroplasticity and nerve regeneration, costs an estimated $12 to $60 a month, and goes up your nose. Cerebrolysin wins…
Semax scores 7.0–7.5/10 against dihexa's 4.0–4.5/10, and that gap is real. Semax wins every cognitive use case we scored and carries human stroke data. Dihexa has zero human…
Neurofeedback, at 7.5–8.0 out of 10 for traumatic brain injury. TBI is a strong practical use case among clinicians and athletes, but the literature is still not definitive.
Of the top-scoring options, Glycine is the least expensive at about $2 a month, scoring 5.0–5.5 out of 10 for traumatic brain injury.
Dihexa scores 3.0–3.5 out of 10 for traumatic brain injury but only 4.0–4.5 overall, landing in the caution tier once safety, side effects, cost and effort are counted.
30 of the 89 interventions evaluated for traumatic brain injury score 3.0 out of 10 or better, which is the cut-off for appearing on this page.
